Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Prothena Corporation plcNASDAQ: PRTA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns positive

Q1 FY2026 income tax expense was $1K, compared with -$1.18M a year earlier. Trailing-twelve-month income tax expense was $45.18M.

Context

  • Income tax expense amounted to 446.7% of revenue in FY2025, up 441.8 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $1K or moves back toward the trailing-twelve-month quarterly average of $11.3M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1K-90.0% QoQ
Last fiscal yearDec 2025
$43.26M+753.5% YoY
LTMMar 2026
$45.18M+907.3% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.1%——
1 year+753.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
43.26M USD
Year-over-year change
+753.5%
4-year CAGR
+72.0%

Income Tax Expense vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +907.3% is the highest of 6, against a peer median of -80.6%.
  • Income tax expense amounts to 78.0% of revenue for PRTA, versus a peer median of 0.2%.
PRTA Competitors
Income Tax Expense for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$45.18M USD+907.3%—78.0%
BIIBBiogen Inc.LTM Jun 2026$21.31M USD-92.0%-44.5%0.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$102K USD+50.0%+69.4%2.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55K USD-80.6%——
AVXLAnavex Life Sciences Corp.LTM Dec 2025$18K USD+114.5%——
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF-100.0%—0.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding PRTA) —-80.6%+12.4%0.2%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.